publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
sive
food
allergi
mark
reactiv
stone
fruit
nut
cannabi
compon
contain
nsltp
phenomenon
crossreact
c
sativa
plant
food
known
cannabi
fruitveget
syndrom
ltp
syndrom
numer
studi
analyz
nsltpmediat
crossreact
c
sativa
stone
fruit
peach
nectarin
plum
addit
nut
appl
tomato
nsltp
belong
prolamin
protein
superfamili
provid
protect
bacteria
fungi
plant
given
import
role
plant
defens
system
nsltp
highli
conserv
result
often
caus
clinic
reactiv
multipl
differ
food
sensit
patient
nsltp
highli
resist
thermal
stress
proteolysi
could
account
abil
withstand
digest
caus
system
reaction
although
oral
allergi
syndrom
also
describ
prior
studi
suggest
nsltpmediat
reactiv
geograph
mainli
europ
report
indic
sensit
stone
fruit
wake
develop
allergi
marijuana
present
case
histori
stone
fruit
allergi
preced
develop
anaphylaxi
c
sativa
compon
rais
novel
possibl
revers
sequenc
nsltp
crossreact
also
might
relev
summari
gather
thorough
allergi
social
histori
essenti
patient
report
allerg
symptom
c
sativa
given
expand
medic
recreat
use
anticip
marijuana
hypersensit
topic
grow
import
field
allergi
case
rais
possibl
addit
marijuana
smoke
handl
nsltpmediat
stone
fruit
crossreact
might
anoth
gateway
c
sativa
sensit
sever
immunodefici
associ
acut
lymphoblast
leukemia
treatment
immunodefici
associ
acut
lymphoblast
leukemia
variou
way
featur
variou
primari
immunodefici
includ
limit
xlink
agammaglobulinemia
chromosom
breakag
disord
ataxia
telangiectasia
haploinsuffici
also
secondari
infect
human
immunodefici
viru
congenit
leukemia
lead
abnorm
newborn
screen
result
sever
combin
immunodefici
could
due
dilut
cell
compar
proport
leukem
cell
addit
lead
immunodefici
secondari
chemotherapi
case
case
seri
sever
immunodefici
extend
followup
describ
present
case
transient
sever
immunodefici
secondari
therapi
infantil
remiss
time
obtain
written
inform
consent
parent
report
patient
born
emerg
cesarean
section
nonconsanguin
parent
week
day
gestat
note
leukemia
cuti
blue
macular
rash
white
blood
cell
count
blast
famili
histori
immunodefici
malign
evalu
diagnos
congenit
preb
aberr
first
day
life
immunophenotyp
show
cell
posit
hladr
tdt
fluoresc
situ
hybrid
show
reciproc
transloc
rearrang
previous
known
mix
lineag
leukemia
gene
rearrang
rearrang
young
age
suggest
highrisk
poor
prognosi
cytogenet
test
neg
trisomi
gene
fusion
gene
delet
poseidon
chromosom
centromer
probe
show
normal
signal
pattern
treat
accord
children
oncolog
group
clinic
treatment
trial
protocol
arm
c
high
risk
age
mix
lineag
leukemia
rearrang
protocol
includ
vincristin
daunorubicin
cyclophosphamid
cytarabin
arac
asparaginas
methylprednisolon
tripl
intrathec
therapi
methotrex
arac
hydrocortison
granulocyt
colonystimul
factor
etoposid
lestaurtinib
complet
remiss
month
age
start
continu
chemotherapi
month
age
plan
complet
therapi
year
age
month
age
develop
rash
occur
monthli
show
improv
transient
intraven
immunoglobulin
therapi
next
month
month
dose
intraven
methotrex
rash
becam
significantli
wors
erythroderma
extrem
face
scalp
overli
thick
yellow
hyperkeratosi
mostli
spare
trunk
fig
chemotherapi
discontinu
month
month
hospit
feed
intoler
vomit
diarrhea
worsen
skin
rash
eventu
transfer
tertiari
care
center
hospit
cours
multipl
infect
includ
klebsiella
septic
shock
extens
workup
hospit
stay
month
age
punch
biopsi
specimen
rash
show
chang
compat
subacut
cytotox
dermat
featur
erythema
multiform
confluent
upper
dermal
necrosi
month
age
note
hypogammaglobulinemia
immunoglobulin
g
mgdl
lymphopenia
lowest
absolut
lymphocyt
count
esophagogastroduodenoscopi
colonoscopi
month
age
show
graftvshost
diseaselik
find
laboratori
find
clinic
cours
present
etabl
telomer
length
studi
normal
whole
exom
sequenc
fail
show
pathogen
variant
gene
associ
sever
combin
immunodefici
known
primari
immunodefici
heterozyg
variant
gene
relat
primari
immunodefici
start
corticosteroid
intraven
immunoglobulin
gkg
sirolimu
clinic
improv
notic
day
start
therapi
corticosteroid
dose
taper
month
start
fungal
pneumocysti
jirovecii
pneumonia
prophylaxi
immunoglobulin
therapi
switch
intraven
subcutan
infus
monitor
close
infect
rash
vomit
diarrhea
continu
show
improv
lymphopenia
show
improv
next
month
month
age
subcutan
immunoglobulin
discontinu
immun
laboratori
result
return
normal
month
age
current
well
year
age
case
demonstr
therapi
associ
complic
sever
combin
immun
dysfunct
prompt
recognit
treatment
support
care
lead
recoveri
transient
sever
immunodefici
patient
immun
reconstitut
chemotherapi
within
month
studi
describ
immun
dysfunct
month
therapi
patient
acut
myeloid
leukemia
note
lymphopenia
hypogammaglobulinemia
howev
clinic
immunolog
featur
describ
patient
case
seri
geerlink
et
al
describ
sever
immunodefici
leukemia
patient
recov
need
hematopoiet
stem
cell
transplant
immun
recoveri
addit
case
studi
children
immunolog
statu
describ
rate
immun
recoveri
howev
none
case
sever
present
case
acknowledg
limit
case
report
child
might
genet
abnorm
yet
complet
manifest
could
miss
exom
sequenc
case
exemplifi
implement
medic
therapi
includ
immunoglobulin
infus
prophylact
antimicrobi
regimen
isol
patient
result
resolut
sever
immunodefici
symptom
await
spontan
tcell
reconstitut
without
need
immun
reconstitut
stem
cell
transplant
